Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): A double-blind, randomised, placebo-controlled phase 3 trial

The Lancet Neurology

Volumn 14, Issue 6, 2015, Pages 575-584

  Albers, Gregory W ^a   von Kummer, Rüdiger ^b   Truelsen, Thomas ^c   Jensen, Jens Kristian S ^c   Ravn, Gabriela M ^c   Grønning, Bjørn A ^c   Chabriat, Hugues ^d   Chang, Ku Chou ^e   Davalos, Antonio E ^f   Ford, Gary A ^g   Grotta, James ^h   Kaste, Markku ⁱ   Schwamm, Lee H ^j   Shuaib, Ashfaq ^k  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c H LUNDBECK A S   (Denmark)

^d HÔPITAL LARIBOISIÈRE   (France)

^e CHANG GUNG UNIVERSITY   (Taiwan)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h MEMORIAL HERMANN HOSPITAL   (United States)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j HARVARD MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DESMOTEPLASE; HEMOGLOBIN; PLACEBO; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR; SALIVARY PLASMINOGEN ACTIVATOR ALPHA 1, DESMODUS ROTUNDUS;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL PNEUMONIA; BRAIN ARTERY; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBRAL ARTERY DISEASE; CEREBRAL ARTERY STENOSIS; CEREBROVASCULAR ACCIDENT; CHRONOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FEMALE; FIBRINOLYTIC THERAPY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SINGLE DRUG DOSE; STROKE PATIENT; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CEREBRAL ARTERIAL DISEASES; CLINICAL TRIAL; COMPLICATION; CONSTRICTION, PATHOLOGIC; MIDDLE AGED; PROCEDURES; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBRAL ARTERIAL DISEASES; CONSTRICTION, PATHOLOGIC; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 84929519483     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00047-2     Document Type: Article

References (17)

1. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995, 333:1581-1587. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischaemic stroke. N Engl J Med 2008, 359:1317-1329.
3. Medcalf RL Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012, 165:75-89.
4. Hacke W, Albers G, Al-Rawi Y, et al. The desmoteplase in acute ischaemic stroke trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005, 36:66-73.
5. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischaemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006, 37:1227-1231.
6. Hacke W, Furlan A, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2008, 8:141-150.
7. Fiebach JB, Al-Rawi Y, Wintermark M, et al. Vascular occlusion enables selecting acute ischaemic stroke patients for treatment with desmoteplase. Stroke 2012, 43:1561-1566.
8. von Kummer R, Albers GW, Mori E The Desmoteplase in Acute Ischaemic Stroke (DIAS) clinical trial program. Int J Stroke 2012, 7:589-596. DIAS Steering Committees.
9. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274:1017-1025.
10. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998, 352:1245-1251.
11. Parsons MW, Christensen S, McElduff P, et al. Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab 2010, 30:1214-1225.
12. Lansberg MG, Thijs VN, Bammer R, et al. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke 2008, 39:2491-2496.
13. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015, 372:1009-1018.
14. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015, 372:1019-1030.
15. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs t-PA alone in stroke. N Engl J Med 2015, for the SWIFT PRIME Investigators, published online April 17. 10.1056/NEJMoa1415061.
16. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375:1695-1703.
17. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014, 384:1929-1935.